<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Savovic T</dc:creator>
  <dc:creator>Prior JO</dc:creator>
  <dc:creator>Nicod-Lalonde M</dc:creator>
  <dc:creator>Bressoud A</dc:creator>
  <dc:creator>Roux S</dc:creator>
  <dc:creator>Schaefer N</dc:creator>
  <dc:creator>Meyer M</dc:creator>
  <dc:date>2019</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">This is the first described case of effective and durable cytoreduction after PRRT with 177Lu-DOTATATE in a 75-year-old female, with B cell chronic lymphoid leukemia, and well-differentiated metastatic neuroendocrine tumor.</dc:description>
  <dc:identifier>https://sonar.ch/global/documents/246728</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1007/s12032-019-1266-0</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/30919094</dc:relation>
  <dc:source>Medical oncology (Northwood, London, England). - 2019</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">117Lu-DOTATATE</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Chronic lymphoid leukemia</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">Neuroendocrine tumor</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">PET/CT</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">PRRT</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">Aged</dc:subject>
  <dc:subject xmlns:ns7="xml" ns7:lang="en">Antineoplastic Agents</dc:subject>
  <dc:subject xmlns:ns8="xml" ns8:lang="en">Cytoreduction Surgical Procedures</dc:subject>
  <dc:subject xmlns:ns9="xml" ns9:lang="en">Dose-Response Relationship, Drug</dc:subject>
  <dc:subject xmlns:ns10="xml" ns10:lang="en">Drug Administration Schedule</dc:subject>
  <dc:subject xmlns:ns11="xml" ns11:lang="en">Female</dc:subject>
  <dc:subject xmlns:ns12="xml" ns12:lang="en">Humans</dc:subject>
  <dc:subject xmlns:ns13="xml" ns13:lang="en">Leukemia, Lymphocytic, Chronic, B-Cell</dc:subject>
  <dc:subject xmlns:ns14="xml" ns14:lang="en">Liver Neoplasms</dc:subject>
  <dc:subject xmlns:ns15="xml" ns15:lang="en">Neuroendocrine Tumors</dc:subject>
  <dc:subject xmlns:ns16="xml" ns16:lang="en">Octreotide</dc:subject>
  <dc:subject xmlns:ns17="xml" ns17:lang="en">Organometallic Compounds</dc:subject>
  <dc:subject xmlns:ns18="xml" ns18:lang="en">Treatment Outcome</dc:subject>
  <dc:title xmlns:ns19="xml" ns19:lang="en">First experience of durable cytoreduction in chronic lymphoid leukemia with 177Lu-DOTATATE.</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>